Latest news and updates related to Angioplasty. Subscribe
to get latest posts via email or subscribe to a RSS feed
Tuesday, August 14, 2018 -- BACKGROUND AND PURPOSE: Although the Stenting versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) study demonstrated a high incidence of perioperative complications for Intracranial Atherosclerotic disease (ICAD) treatments with stent placement, some studies have shown that submaximal angioplasty with an undersized balloon limits the risks of perioperative complications, suggesting that intervention may remain an alternative option for ICAD if perioperative complications are minimized. We sought to evaluate clinical and angiographic outcomes after primary angioplasty without stent placement in patients with symptomatic, high-grade intracranial stenosis and poor antegrade flow who were refractory to medical therapy. MATERIALS AND METHODS: All cases with high-grade, symptomatic intracranial stenosis and poor antegrade flow treated with intracranial angioplasty without stent placement
Monday, May 21, 2018 -- AbstractObjectives The aim of this study was to assess the performance of the fluoropolymer-based paclitaxel-eluting stent (PES) in long femoropopliteal lesions. Background The new-generation fluoropolymer-based PES showed promising outcomes in short femoropopliteal lesions. The main feature of the stent is its controlled and sustained paclitaxel release over 12 months. However, the safety and efficacy of this technology in longer femoropopliteal lesions remain unclear. Methods Between March 2016 and March 2017, 62 patients were included in this analysis. Indications for fluoropolymer-based PES deployment were insufficient luminal gain or flow-limiting dissection after plain old balloon angioplasty in a femoropopliteal lesion. Primary patency, freedom from target lesion revascularization, amputation-free survival, and paclitaxel-related adverse events were retrospectively analyzed for up to 1 year
Monday, May 21, 2018 -- AbstractObjectives The aim of this study was to investigate the impact of optimizing procedure-related factors during drug-eluting balloon (DEB) angioplasty on clinical outcomes of drug-eluting stent in-stent restenosis (ISR). Background Although DEB angioplasty is recommended as a reasonable option for ISR, recurrent target lesion failure (TLF) still occurs in many patients after DEB angioplasty. Methods Consecutive patients with drug-eluting stent ISR treated with DEB (SeQuent Please) were collected from 4 centers in Korea. The primary outcome was 2-year TLF. Procedure-related modifiable independent predictors for TLF and their best cutoff values were determined. Results In a total of 256 patients (309 lesions), TLF occurred in 52 patients (20.3%). Modifiable independent predictors of TLF among procedure-related factors were residual diameter stenosis
Wednesday, May 02, 2018 -- Percutaneous transluminal angioplasty maybe beneficial for reducing headaches in relapsing remitting and secondary progressive multiple sclerosis.
Wednesday, April 18, 2018 -- Overall vessel expansion induced by a stretch of the arterial wall led to lumen enlargement immediately after balloon pulmonary angioplasty, according to results recently published in Circulation: Cardiovascular Interventions.The data also show that lesion type may dictate the amount of fibrous tissue, making it beneficial to change the balloon size in correlation with the lesion type.“Balloon pulmonary angioplasty has become a therapeutic option for patients with chronic thromboembolic pulmonary hypertension who are ineligible for pulmonary endarterectomy. Previous [studies]